ARTICLE | Product Development
What’s next for the ADC after it extends PFS in breast cancer patients with barely detectable HER2
By Lauren Martz, Executive Director, Biopharma Intelligence
June 4, 2024 11:54 PM UTC
Enhertu has surpassed expectations again, with ASCO data proving efficacy in breast cancers when even the lowest detectable amount of HER2 expression is present. There are now data to support Enhertu’s use across the large majority of advanced and metastatic previously treated breast cancers, but AstraZeneca and Daiichi aren’t finished with breast cancer yet.
The next tests will be whether the HER2-targeted antibody-drug conjugate (ADC) can deliver the same — or even more impressive — results outside the metastatic setting, and whether the safety profile supports use in those applications…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652605/az-daiichi-see-more-enhertu-opportunity-in-breast-cancer-after-her2-ultralow-asco-data